



**PHARMACY AND THERAPEUTICS COMMITTEE  
ACA/Exchange MEETING MINUTES  
October 26, 2023**

*Attendance: Microsoft Teams Meeting  
Rakel Beall-Wilkins, Magellan Health; Connie Chan, Staff/Clinical Pharmacist; Edgar Chou, Jefferson Health; Jerry Crawford, Staff/Clinical Pharmacist; Dr. Neal Demp, Community Behavior Health; Danielle Dolores, Director of Pharmacy; George E. Downs, Dean Emeritus and Professor, St. Joseph's University; Leah Finken, Clinical Programs Pharmacist; Sharon Ford, Staff/Clinical Pharmacist; Paul Goebel, Enterprise Director Clinical Pharmacy programs, Jefferson Health; Merleen Harris-Williams, Medical Director; Samantha Jackson, Clinical Pharmacist; Ruth John, Pharmacy Student Intern; Lawrence Jones, Executive Director, Pennsylvania Society of Health-System Pharmacists (PSHP); Kaylei Koerwitz, Manager Pharmacy Operations and Clinical Programs; Dr. Tania Kolev, Medical Director; Christina Le, Pharmacy Student Intern; Brandi Mahler, Supervisor Pharmacy Technicians; Hannah McCaffrey, Manager Pharmacy Regulations & Implementation; Karleen Melody; Kateryna Olchowecky, Clinical Programs Pharmacist; Maryana Prokopets, Staff/Clinical Pharmacist; Sanjiv Raj, Associate VP Customer Engagement; Sara Sadiq, Pharmacist; Julie Samuel, Clinical Programs Pharmacist; Robert Spencer, Staff/Clinical Pharmacist; Dr. Chris Squillaro, Medical Director, Magellan Behavioral Health; Justin Steffan, Pharmacy Resident; Brian Swift, Enterprise Vice President/Chief Pharmacy Officer, Jefferson Health; Jessica Tran, Staff/Clinical Pharmacist; Fallan Vaisberg, Formulary Pharmacist; Ramesh Vangala, Vice President of Pharmacy Operations; Jeanine Zubrzycki, Staff/Clinical Pharmacist*

*Excused: Justin Bittner, Medical Director; Gary Bledsoe, Staff/Clinical Pharmacist; Kay Chan, Manager Pharmacy Benefit Design and Audits; Demian Elder, Medical Director; Oluwatoyin Fadeyibi, Community Behavior Health; Heather Scheckner, Clinical Pharmacist, Jefferson Health; Mike Smikovec, Staff/Clinical Pharmacist; Shelley Staffa, Clinical Pharmacist*

*Minutes taken by: Joana Iverson*

**I. Administrative Update**

TOPIC	DISCUSSION	ACTIONS	RESPONSIBLE PARTY	RESOLVED/PENDING
<b>Minutes Review/Approval</b>	D. Dolores presented the minutes from the August 2023 meeting to the Committee for review.	The Committee approved the minutes from our last meeting as presented.	D. Dolores	Resolved
<b>2024 Approval Updates</b>	H. McCaffrey discussed approval updates	H. McCaffrey provided approval updates	H. McCaffrey	Informational
<b>Policies and Procedures</b>	D. Dolores reviewed Policies & Procedures for the ACA line of business <ul style="list-style-type: none"> <li>Pharmacy Prior Authorization</li> </ul>	D. Dolores reviewed Policies & Procedures	D. Dolores	Informational

TOPIC	DISCUSSION	ACTIONS	RESPONSIBLE PARTY	RESOLVED/PENDING
	<ul style="list-style-type: none"> <li>Pharmacy Operations and Responsibilities</li> <li>Pharmacy Formulary Management</li> <li>Pharmacy Vendor Management</li> <li>Pharmacy and Therapeutics (P&amp;T) Committee</li> <li>Drug Utilization Review</li> </ul>			
<b>Open Enrollment</b>	<i>H. McCaffrey discussed open enrollment occurring 11/1/2023 through 12/15/2023</i>	<i>H. McCaffrey discussed open enrollment</i>	<i>H. McCaffrey</i>	<i>Informational</i>


## II. Drug Formulary Review/Update

TOPIC	DISCUSSION	ACTIONS	RESPONSIBLE PARTY	RESOLVED/PENDING
<b>2024 Formulary Additions</b>	<p><i>The Committee reviewed the 2024 Formulary Additions. The Committee approved as presented.</i></p> <ul style="list-style-type: none"> <li><i>Breo Ellipta inhaler 50-25 mcg - Preferred Brands, QL</i></li> <li><i>Cresemba cap 74.5 mg - Non-Preferred Drug, PA</i></li> <li><i>Fragmin injection 2500/mL - Non-Preferred Drug</i></li> <li><i>Mircera injection 120 mcg - Specialty, PA</i></li> <li><i>Phenytek cap 300 mg - Generics</i></li> <li><i>Phenytek cap 200 mg - Generics</i></li> <li><i>Yargesa 100 mg cap - Specialty, PA</i></li> </ul>	<i>The Committee approved as presented. The 2024 Formulary Additions will be sent to PARP for approval.</i>	<i>H. McCaffrey</i>	<i>Resolved</i>

<b>III. Prior Authorization Review</b>	<p><i>The Committee reviewed and approved as presented.</i></p> <ul style="list-style-type: none"> <li><i>Non-formulary exception/tiering policy</i></li> <li><i>ACA Preventive Medication \$0 copay exception policy</i></li> </ul>	<i>The Committee reviewed and approved as presented.</i>	<i>H. McCaffrey</i>	<i>Resolved</i>
<b>IV. New Drug Review</b>	<i>Refer to the Medicaid New Drug Review</i>		<i>H. McCaffrey</i>	<i>Resolved</i>

## V. Adjournment

There being no further business to discuss, the meeting was adjourned. Next meeting is to be held February 2024.



11/14/23

\_\_\_\_\_  
Danielle Dolores, Director of Pharmacy Services

\_\_\_\_\_  
Date